| abstract |
The present invention provides compounds for use as medicaments which act by inhibiting CYP17A1 enzymes and CYP19A1 enzymes. The compounds have particular application in the treatment of cancer, especially prostate and breast cancer. Described compound has following formula: [chemical formula 1] Wherein: R is independently selected from: optionally substituted aromatic amides; optionally substituted alkyl aromatic amides; optionally substituted aryl formamides; optionally substituted cyanopiperidines; optionally substituted oxopiperidines optionally substituted N-(pyridin-3-yl); optionally substituted pyridin-3-yl; optionally substituted pyrazole-4-carboxamide; optionally substituted pyrimidin-4-ylcarboxamide; Optionally substituted pyrimidin-4-ylcarboxamide; optionally substituted 1H-pyrrol-2-ylcarboxamide; optionally substituted morpholinecarboxamide; optionally substituted 1H-indazol-3-ylcarboxamide; Optionally substituted 5-cyanopiperidin-3-ylcarboxamide; optionally substituted quinolin-7-yl; optionally substituted pyrazin-2-ylcarboxamide; optionally substituted 1H-1,3- benzodiazol-6-carboxamide; and optionally substituted 3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-ylcarboxamide; each of R1, R2, R3, R4, R5 are independently selected from: H; OH; a halogen atom; OCH3 ; and NH2 ; and X is independently selected from O, H and OH. Some compounds are claimed per se, and the invention also includes pharmaceutically acceptable salts, solvates, hydrates, primary metabolites and prodrugs thereof. |